Date	e:Dec.25th, 2021			
			protein 1 Inhibits the Proliferation of Lung	
	nocarcinoma via Regulating			
	nuscript number (if known):			
rela part to ti	ted to the content of your m ties whose interests may be a	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment if you are in doubt about whether to list a	
	following questions apply to	the author's relationships/	activities/interests as they relate to the <u>current</u>	
to tl	ne epidemiology of hyperten		ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive	IS
med	ncation, even ii that medicat	non is not inclitioned in the	manuscript.	
In it		port for the work reported i	in this manuscript without time limit. For all other ite	ems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	n this manuscript without time limit. For all other ite	ems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	n this manuscript without time limit. For all other ite	ems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or	n this manuscript without time limit. For all other ite	ems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	n this manuscript without time limit. For all other ite	ems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	tem #1 below, report all supp time frame for disclosure is	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present manuscript (e.g., funding,	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	All support for the present manuscript (e.g., funding, provision of study materials,	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Date	e:Dec.25th, 2021			
			protein 1 Inhibits the Proliferation of Lung	
	nocarcinoma via Regulating			
	nuscript number (if known):			
rela part to ti	ted to the content of your m ties whose interests may be a	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a	
	following questions apply to	the author's relationships/	activities/interests as they relate to the <u>current</u>	
to tl	ne epidemiology of hyperten		ined broadly. For example, if your manuscript pertain relationships with manufacturers of antihypertensive	
meu	ncation, even ii that medicat	non is not inclitioned in the	manuscript.	
In it		port for the work reported i	n this manuscript without time limit. For all other ito	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	n this manuscript without time limit. For all other ite	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	n this manuscript without time limit. For all other its	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or	n this manuscript without time limit. For all other ite	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	n this manuscript without time limit. For all other its	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	n this manuscript without time limit. For all other ite	ems,
In it	tem #1 below, report all supp time frame for disclosure is	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	n this manuscript without time limit. For all other ite	tems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	n this manuscript without time limit. For all other ite	tems,
In it	tem #1 below, report all supp time frame for disclosure is	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	n this manuscript without time limit. For all other ite	tems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present manuscript (e.g., funding,	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	n this manuscript without time limit. For all other ite	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	n this manuscript without time limit. For all other ite	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials,	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	n this manuscript without time limit. For all other ite	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialX_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	port for the work reported is the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Data	e:Dec.25th, 2021		
	r Name: An-Ping Shi		·
		ulation of Fibrinogen-like-r	protein 1 Inhibits the Proliferation of Lung
	nocarcinoma via Regulating		Times we I tomes with a Lung
rela part to ti	ted to the content of your m	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	following questions apply to	o the author's relationships/	activities/interests as they relate to the current_
to tl	_	sion, you should declare all	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	n this manuscript without time limit. For all other items,
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	(e.g., it payments were made to you of to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	paraming of the work
	manuscript (e.g., funding,		
	1 (0)		
	provision of study materials,		
	provision of study materials, medical writing, article		
	provision of study materials, medical writing, article processing charges, etc.)		
	provision of study materials, medical writing, article	Time frame: post	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: past	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	Time frame: past	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item		36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any		36 months

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Dat	e:Dec.25th, 2021		
You	ır Name:Ying Sun		
			orotein 1 Inhibits the Proliferation of Lung
	enocarcinoma via Regulating		S
	nuscript number (if known):		
rela	ited to the content of your ma	anuscript. "Related" means	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third
-	-	<u>-</u>	e manuscript. Disclosure represents a commitment
	ransparency and does not ne itionship/activity/interest, it i	-	f you are in doubt about whether to list a
ıcıa	ttionship/activity/interest, it i	is preierable that you do so.	
	e following questions apply to nuscript only.	o the author's relationships/	activities/interests as they relate to the <u>current</u>
to t	-	sion, you should declare all	ned broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.
	tem #1 below, report all supp time frame for disclosure is	•	n this manuscript without time limit. For all other items.
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	(•g, puj)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	r.
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	X_None	
	entity (if not indicated in item		
	#1 above).		
3	#1 above). Royalties or licenses	XNone	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Dat	e:Dec.25th, 2021		
You	ır Name:Qing Han		
Mai	nuscript Title: The Downreg	ulation of Fibrinogen-like-p	orotein 1 Inhibits the Proliferation of Lung
Ade	enocarcinoma via Regulating	MYC-target genes	<u> </u>
Mai	nuscript number (if known):		
rela par	ted to the content of your m ties whose interests may be a	anuscript. "Related" means	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment
	ransparency and does not ne itionship/activity/interest, it	-	f you are in doubt about whether to list a
	following questions apply to	o the author's relationships/	activities/interests as they relate to the <u>current</u>
to t		sion, you should declare all	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	n this manuscript without time limit. For all other items,
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	(e.g., it payments were made to you of to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	manuscript (e.g., runding,		
	provision of study materials,		
	provision of study materials, medical writing, article		
	provision of study materials, medical writing, article processing charges, etc.)		
	provision of study materials, medical writing, article	Time frame: neet	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: past	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	Time frame: past _X_None	36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item		36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any		36 months

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Dat	e:Dec.25th, 2021		
	ır Name:Yao Lv		
			orotein 1 Inhibits the Proliferation of Lung
	nocarcinoma via Regulating	•	C
	nuscript number (if known):		
rela par to t	ted to the content of your m	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	following questions apply to	o the author's relationships/	activities/interests as they relate to the <u>current</u>
to t	•	sion, you should declare all	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.
	tem #1 below, report all supp time frame for disclosure is	•	n this manuscript without time limit. For all other items
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	(ag) Pag a management growth and a management growth gro
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	X None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	X None	
-	entity (if not indicated in item		
	#1 above).		
	, , , , , , , , , , , , , , , , , , ,	X None	
3	Royalties or licenses		

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Date	e:Dec.25th, 2021			
			protein 1 Inhibits the Proliferation of Lung	
	nocarcinoma via Regulating			
	nuscript number (if known):	, , ,		
rela part to ti	ted to the content of your m	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment of you are in doubt about whether to list a	
	following questions apply to	o the author's relationships/	activities/interests as they relate to the <u>current</u>	
to tl	ne epidemiology of hyperten		ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive	
mea	ncation, even ii that medicat	non is not inclitioned in the	manuscript.	
In it		port for the work reported i	in this manuscript without time limit. For all other ite	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	in this manuscript without time limit. For all other ite	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months.	n this manuscript without time limit. For all other its	tems,
In it	em #1 below, report all supp	port for the work reported i the past 36 months. Name all entities with whom you have this relationship or	in this manuscript without time limit. For all other ite	tems,
In it	em #1 below, report all supp	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	n this manuscript without time limit. For all other its	tems,
In it	em #1 below, report all supp	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	em #1 below, report all supp	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	tem #1 below, report all supp time frame for disclosure is	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	tem #1 below, report all supptime frame for disclosure is All support for the present manuscript (e.g., funding,	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials,	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial _X_None	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,
In it the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	port for the work reported in the past 36 months. Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	tems,

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Date:	_2022/2/9
Your Name:	Milo Frattini
Manuscript Title:	_ The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinon
via regulating MYC-	arget genes
Manuscript number	if known):
•	•

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			plaining of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Date:	_2022/2/9
Your Name:	Jyoti Malhotra
Manuscript Title:	_ The downregulation of fibrinogen-like protein 1 inhibits the proliferation of lung adenocarcinoma
via regulating MYC-ta	arget genes
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	_		
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		
ы.		COLUMN CO	· Harantana Karantana

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Dat	e:Dec.25th, 2021		
	ır Name: Kai-Fu Zheng		
			protein 1 Inhibits the Proliferation of Lung
	enocarcinoma via Regulating	•	
	nuscript number (if known):		
rela par to t	tted to the content of your m ties whose interests may be a	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a
	e following questions apply to nuscript only.	o the author's relationships/	activities/interests as they relate to the <u>current</u>
to t med In i	he epidemiology of hyperten lication, even if that medicat	sion, you should declare all tion is not mentioned in the port for the work reported i	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript. n this manuscript without time limit. For all other items,
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.) No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	XNone	
	entity (if not indicated in item		
	#1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			_
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	XNone		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_				
	lone.			
DI.		-N		

Date	e:Dec.25th, 2021			
			protein 1 Inhibits the Proliferation of Lung	
	nocarcinoma via Regulating	•		
	,	:		
rela part to ti	ted to the content of your m ties whose interests may be a ransparency and does not no	anuscript. "Related" means	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a	
	following questions apply t nuscript only.	o the author's relationships/	activities/interests as they relate to the <u>current</u>	
to the med	ne epidemiology of hyperten lication, even if that medica	sion, you should declare all tion is not mentioned in the port for the work reported i	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript. n this manuscript without time limit. For all other items	š ,
		Name all entities with whom	Specifications/Comments	
		you have this relationship or	(e.g., if payments were made to you or to your institution)	
		indicate none (add rows as	(e.g., it payments were made to you or to your institution)	
		needed)		
		Time frame: Since the initial	planning of the work	
1	All support for the present	X None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			
		Time frame; past	36 months	
2	No time limit for this item.	Time frame: past	36 months	
2	No time limit for this item. Grants or contracts from any		36 months	
2	No time limit for this item. Grants or contracts from any entity (if not indicated in item		36 months	
2	No time limit for this item. Grants or contracts from any		36 months	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	X_None		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_	lana			
	lone.			
D1 -		-N		

	e: Dec.25th, 2021			
	r Name: Tao Jiang			
			protein 1 Inhibits the Proliferation of Lung	
	nocarcinoma via Regulating	•	a colonia i ministra che i i conte unon di Eung	
	nuscript number (if known):			
1,141	augeripe number (ir anown).			
rela part to ti	ted to the content of your maties whose interests may be a	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a	
	following questions apply to	o the author's relationships/	activities/interests as they relate to the <u>current</u>	
to tl	_	sion, you should declare all	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.	S
	tem #1 below, report all supp time frame for disclosure is	•	n this manuscript without time limit. For all other ite	ems,
		the past 36 months.		ems,
		the past 36 months. Name all entities with whom	Specifications/Comments	ems,
		the past 36 months.		ems,
		the past 36 months. Name all entities with whom	Specifications/Comments	ems,
		Name all entities with whom you have this relationship or	Specifications/Comments	ems,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	time frame for disclosure is	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	All support for the present	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)	ems,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial _X_None Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial _X_None Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial _X_None Time frame: past	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work	ems,

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	X_None		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_	lana			
	lone.			
D1 -		-N		

Dat	e:Dec.25th, 2021		
	ır Name: Nan Ma		
	<u> </u>		protein 1 Inhibits the Proliferation of Lung
	enocarcinoma via Regulating		7. VVIII. 2 VIII. VIII. VIII. VIII. VIII. VIII. ZIII. III.
	nuscript number (if known):		
	•		
rela par to t	ited to the content of your mities whose interests may be a	anuscript. "Related" means affected by the content of the ecessarily indicate a bias.	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment of you are in doubt about whether to list a
	e following questions apply to	o the author's relationships/	activities/interests as they relate to the <u>current</u>
to t med In i	he epidemiology of hyperten lication, even if that medicat	sion, you should declare all tion is not mentioned in the port for the work reported i	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript. In this manuscript without time limit. For all other items
		Name all antition with whom	Swarfingtions/Comments
		Name all entities with whom	Specifications/Comments
		you have this relationship or	(e.g., if payments were made to you or to your institution)
		indicate none (add rows as	
		needed)	
1	A11	Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	1		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	XNone	
	1		
	entity (if not indicated in item		
	entity (if not indicated in item #1 above).		
3		X_None	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	X_None		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_	lana			
	lone.			
D1 -		-N		

You	te:Dec.25th, 2021			
	ur Name:Jin-Bo Zhao_			
Ma			orotein 1 Inhibits the Proliferation of Lung	
Ade	enocarcinoma via Regulating	g MYC-target genes	<u> </u>	
Ma	nuscript number (if known):	·		
rela par	ated to the content of your m ties whose interests may be a	anuscript. "Related" means	lationships/activities/interests listed below that are any relation with for-profit or not-for-profit third e manuscript. Disclosure represents a commitment f you are in doubt about whether to list a	
	ationship/activity/interest, it	-	Tyou are in doubt about whether to list a	
	e following questions apply to	o the author's relationships/	activities/interests as they relate to the current_	
to t	-	sion, you should declare all	ined broadly. For example, if your manuscript pertains relationships with manufacturers of antihypertensive manuscript.	
	item #1 below, report all sup time frame for disclosure is	•	n this manuscript without time limit. For all other iten	ns,
		Name all entities with whom	Specifications/Comments	
		Name all entities with whom	Specifications/Comments (a.g., if payments were made to you or to your institution)	
		you have this relationship or	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		you have this relationship or indicate none (add rows as		
		you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
1	All support for the present	you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution)	
1	All support for the present manuscript (e.g., funding,	you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding,	you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials,	you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article	you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials,	you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution)	
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	(e.g., if payments were made to you or to your institution) planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	(e.g., if payments were made to you or to your institution) planning of the work	
1 2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	(e.g., if payments were made to you or to your institution) planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	(e.g., if payments were made to you or to your institution) planning of the work	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any	you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone Time frame: past	(e.g., if payments were made to you or to your institution) planning of the work	

4	Consulting fees	XNone		
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers			
	bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role in	XNone		
	other board, society, committee			
	or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	XNone		
	materials, drugs, medical			
	writing, gifts or other services			
13	Other financial or non-financial	X_None		
	interests			
Plea	se summarize the above con	flict of interest in the follow	ving box:	
_	lana			
	lone.			
D1 -		-N		